Literature DB >> 26238780

Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.

Gregory N Adams1, Leah Rosenfeldt1, Malinda Frederick1, Whitney Miller1, Dusty Waltz1, Keith Kombrinck1, Kathryn E McElhinney1, Matthew J Flick1, Brett P Monia2, Alexey S Revenko2, Joseph S Palumbo3.   

Abstract

Thrombin-mediated proteolysis is a major determinant of metastasis, but is not universally important for primary tumor growth. Here, we report that colorectal adenocarcinoma represents one important exception whereby thrombin-mediated functions support both primary tumor growth and metastasis. In contrast with studies of multiple nongastrointestinal cancers, we found that the growth of primary tumors formed by murine and human colon cancer cells was reduced in mice by genetic or pharmacologic reduction of circulating prothrombin. Reduced prothrombin expression was associated with lower mitotic indices and invasion of surrounding tissue. Mechanistic investigations revealed that thrombin-driven colonic adenocarcinoma growth relied upon at least two targets of thrombin-mediated proteolysis, protease-activated receptor-1 (PAR-1) expressed by stromal cells and the extracellular matrix protein, fibrinogen. Colonic adenocarcinoma growth was reduced in PAR-1-deficient mice, implicating stromal cell-associated PAR-1 as one thrombin target important for tumor outgrowth. Furthermore, tumor growth was dramatically impeded in fibrinogen-deficient mice, offering the first direct evidence of a critical functional role for fibrinogen in malignant tumor growth. Tumors harvested from fibrinogen-deficient mice displayed a relative reduction in cell proliferative indices, as well as increased tumor necrosis and decreased tumor vascular density. Collectively, our findings established a functional role for thrombin and its targets PAR-1 and fibrinogen in the pathogenesis of colonic adenocarcinoma, supporting tumor growth as well as local invasion and metastasis. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26238780      PMCID: PMC4809049          DOI: 10.1158/0008-5472.CAN-15-0964

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

Review 1.  Platelets in tissue repair: control of apoptosis and interactions with regenerative cells.

Authors:  Meinrad Gawaz; Sebastian Vogel
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

2.  Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice.

Authors:  N Yokota; A Zarpellon; S Chakrabarty; V Y Bogdanov; A Gruber; F J Castellino; N Mackman; L G Ellies; H Weiler; Z M Ruggeri; W Ruf
Journal:  J Thromb Haemost       Date:  2014-01       Impact factor: 5.824

3.  Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner.

Authors:  Begüm Kocatürk; Yascha W Van den Berg; Chris Tieken; J Sven D Mieog; Esther M de Kruijf; Charla C Engels; Martijn A van der Ent; Peter J Kuppen; Cornelis J Van de Velde; Wolfram Ruf; Pieter H Reitsma; Susanne Osanto; Gerrit-Jan Liefers; Vladimir Y Bogdanov; Henri H Versteeg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-25       Impact factor: 11.205

Review 4.  Tissue factor and cancer.

Authors:  Wolfram Ruf
Journal:  Thromb Res       Date:  2012-10       Impact factor: 3.944

Review 5.  Fibrinogen as a key regulator of inflammation in disease.

Authors:  Dimitrios Davalos; Katerina Akassoglou
Journal:  Semin Immunopathol       Date:  2011-10-31       Impact factor: 9.623

Review 6.  Thrombin and vascular inflammation.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  Mol Cell Biochem       Date:  2011-08-23       Impact factor: 3.396

7.  Clotting factor gene polymorphisms and colorectal cancer risk.

Authors:  Carla Y Vossen; Michael Hoffmeister; Jenny C Chang-Claude; Frits R Rosendaal; Hermann Brenner
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

Review 8.  Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects.

Authors:  Jolanta M Siller-Matula; Michael Schwameis; Andrew Blann; Christine Mannhalter; Bernd Jilma
Journal:  Thromb Haemost       Date:  2011-10-06       Impact factor: 5.249

9.  Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain.

Authors:  Eric S Mullins; Keith W Kombrinck; Kathryn E Talmage; Maureen A Shaw; David P Witte; Joni M Ullman; Sandra J Degen; William Sun; Matthew J Flick; Jay L Degen
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

Review 10.  Platelets as cellular effectors of inflammation in vascular diseases.

Authors:  Matthew T Rondina; Andrew S Weyrich; Guy A Zimmerman
Journal:  Circ Res       Date:  2013-05-24       Impact factor: 17.367

View more
  43 in total

1.  Mechanistic insights into thrombin's switch between "slow" and "fast" forms.

Authors:  Jiajie Xiao; Ryan L Melvin; Freddie R Salsbury
Journal:  Phys Chem Chem Phys       Date:  2017-09-20       Impact factor: 3.676

2.  Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning.

Authors:  Jiajie Xiao; Ryan L Melvin; Freddie R Salsbury
Journal:  J Biomol Struct Dyn       Date:  2018-03-02

3.  Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.

Authors:  Yi Yang; Amanda Stang; Patrick G Schweickert; Nadia A Lanman; Erin N Paul; Brett P Monia; Alexey S Revenko; Joseph S Palumbo; Eric S Mullins; Bennett D Elzey; Edith M Janssen; Stephen F Konieczny; Matthew J Flick
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

4.  Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice.

Authors:  G N Adams; B K Sharma; L Rosenfeldt; M Frederick; M J Flick; D P Witte; L O Mosnier; E Harmel-Laws; K A Steinbrecher; J S Palumbo
Journal:  J Thromb Haemost       Date:  2018-09-27       Impact factor: 5.824

5.  Rivaroxaban does not affect growth of human pancreatic tumors in mice.

Authors:  Anaum Maqsood; Yohei Hisada; Kenison B Garratt; Jonathon Homeister; Nigel Mackman
Journal:  J Thromb Haemost       Date:  2019-08-26       Impact factor: 5.824

Review 6.  Targeting PAR1: Now What?

Authors:  Robert Flaumenhaft; Karen De Ceunynck
Journal:  Trends Pharmacol Sci       Date:  2017-05-27       Impact factor: 14.819

7.  Na+-binding modes involved in thrombin's allosteric response as revealed by molecular dynamics simulations, correlation networks and Markov modeling.

Authors:  Jiajie Xiao; Freddie R Salsbury
Journal:  Phys Chem Chem Phys       Date:  2019-02-20       Impact factor: 3.676

Review 8.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

Review 9.  Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype.

Authors:  Abigail C Cornwell; Michael E Feigin
Journal:  Trends Pharmacol Sci       Date:  2020-10-22       Impact factor: 14.819

Review 10.  The Immune Microenvironment and Cancer Metastasis.

Authors:  Asmaa El-Kenawi; Kay Hänggi; Brian Ruffell
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.